What is Athersys Inc?
Athersys Inc is a biotechnology enterprise dedicated to the discovery and development of therapeutic product candidates aimed at enhancing human health. The company's core asset, MultiStem, represents a significant advancement in regenerative medicine, utilizing adult-derived stem cells to treat complex diseases. By maintaining a robust network of strategic partnerships and collaborations, Athersys positions itself at the intersection of clinical innovation and commercial scalability. The firm's focus remains on validating its therapeutic candidates through rigorous clinical evaluation, ensuring that its regenerative solutions can effectively transition from laboratory research to standard-of-care medical applications.
How much funding has Athersys Inc raised?
Athersys Inc has raised a total of $264.5M across 9 funding rounds:
Share Placement
$9M
Debt
$25M
Stock Offering
$23M
Debt
$100M
Share Placement
$7M
Share Placement
$12M
Other Financing Round
$10.4M
Share Placement (2012): $9M supported by Undisclosed
Debt (2013): $25M featuring Aspire Capital
Stock Issuance/Offering (2017): $23M backed by Undisclosed
Debt (2018): $100M with participation from Aspire Capital
Share Placement (2020): $7M led by Healios
Share Placement (2022): $12M, investors not publicly disclosed
Other Financing Round (2023): $10.4M, investors not publicly disclosed
Key Investors in Athersys Inc
Pappas Ventures
Pappas Capital is a leading healthcare venture capital firm that specializes in advancing biopharma, biotech, and medical technologies aimed at improving patient outcomes.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
What's next for Athersys Inc?
Looking ahead, Athersys is poised to leverage its recent capital infusion to accelerate the clinical development of its MultiStem platform. The strategic focus will likely remain on optimizing trial outcomes and strengthening commercialization pathways for its neurological and cardiovascular indications. As the company matures, the integration of data-driven insights from its ongoing clinical trials will be paramount in securing future partnerships and maintaining its competitive edge in the high-stakes biotechnology landscape. The firm's ability to sustain its research momentum will be critical as it moves toward potential regulatory milestones and broader market adoption of its regenerative therapies.
See full Athersys Inc company page
